EBMT-EHA CAR-T 2019 | The challenges in treating AML with CAR T-cell therapy
Elizabeth Budde, MD, PhD City of Hope National Medical Center, Duarte, CA, discusses the characterisics of acute myeloid leukemia and how they impact the utilization of CAR T-cell therapy in the treatment of the disease. Dr Budde was speaking at the 1st European CAR T-Cell Meeting, held in Paris, France, co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and the European Hematology Association (EHA).
Transcript (edited for clarity):
AML patients now are very different than patients with other blood cancers. Now these patients typically they tend to have a lot of complications. And while they’re waiting for the CAR T-cells to be made …
For example, in our trials now, we consented 24 patients but we’re only able to give CAR-T to 50% of them. And the other 50% of patients were not able to receive CAR-T and the main reason is that because of disease progression that lead to patient death and also there are patient who also died from severe opportunistic infections.
So these are all the real world challenge now, taking care of these patients. So definitely there needs to be a way to really accelerate the production time. And also better supportive care for these patients. And perhaps now being more creative in making … or banking the patients immune cells prior to their disease and their progression in patient who are high risk.
Get great new content delivered to your inboxSign up